Joe Y Chang, Professor and Clinical Section Chief at MD Anderson Cancer Center, shared a post on X:
“First phase III randomized study showed an improvement in overall survival with proton-based IMPT compared to photon IMRT in head and neck cancer.
This was presented today during the The Particle Therapy Co-Operative Group (PTCOG) plenary session by Steven J. Frank.
The exciting data provides justification for IMPT.”
More posts featuring Joe Y Chang on OncoDaily.